CP 001

Drug Profile

CP 001

Alternative Names: CP001

Latest Information Update: 11 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Caelus Health
  • Developer Caelus Health; Johnson & Johnson Innovation
  • Class Antihypoglycaemics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Metabolic syndrome; Type 2 diabetes mellitus

Most Recent Events

  • 05 Jan 2017 Caelus Health enters into a collaboration with Johnson & Johnson Innovation for the development of CP-001
  • 05 Jan 2017 Phase-I clinical trials in Metabolic syndrome in Netherlands prior to January 2017 (PO) (Caelus Health Pipeline January 2017)
  • 05 Jan 2017 Phase-I clinical trials in Type-2-diabetes mellitus prevention in Netherlands prior to January 2017 (PO) (Caelus Health Pipeline January 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top